XML 42 R26.htm IDEA: XBRL DOCUMENT v3.23.3
Collaboration and license agreements (Tables)
 9 Months Ended
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Summary of allocation of transaction price
The following table summarizes the allocation of the total transaction price to the identified performance obligations under the arrangement, and the amount of the transaction price unsatisfied as of September 30, 2023 (in thousands):
Transaction
Price
Allocated		Transaction
Price
Unsatisfied
Performance obligations:  
Research and development targets$61,149 $17,722 
Option rights6,757 1,670 
Total$67,906 $19,392 
Schedule of revenue from collaboration agreements
Revenue from collaboration agreements for the three and nine months ended September 30, 2023 and 2022 in the condensed consolidated statements of operations and comprehensive loss was as follows (in thousands):
 Three Months Ended September 30,Nine Months Ended September 30,
 2023202220232022
Revenue from collaboration agreements:  
Roche Agreement$8,223 $875 $8,736 $4,548 
Biogen Agreement2,849 4,100 7,689 18,350 
Calico Agreement— 1,779 1,070 5,344 
Total revenue from collaboration agreements$11,072 $6,754 $17,495 $28,242 
Schedule of financial information related to collaboration and license agreements
Financial information related to the collaboration and license agreements consisted of the following in the Company’s condensed consolidated balance sheet as of September 30, 2023 (in thousands):
 Accounts
Receivable		Deferred Revenue,
Current		Deferred Revenue,
Net of Current		Deferred Revenue,
Total
Supplemental information:    
Roche Agreement$500 $2,464 $11,845 $14,309 
Biogen Agreement— 3,738 — 3,738 
Calico Agreement— — — — 
Betta Agreements— 2,222 7,778 10,000 
Total$500 $8,424 $19,623 $28,047 
Financial information related to the collaboration and license agreements consisted of the following in the Company’s condensed consolidated balance sheet as of December 31, 2022 (in thousands):
 Accounts
Receivable		Deferred Revenue,
Current		Deferred Revenue,
Net of Current		Deferred Revenue,
Total
Supplemental information:    
Roche Agreement$417 $4,649 $16,895 $21,544 
Biogen Agreement— 11,427 — 11,427 
Calico Agreement1,056 542 — 542 
Total$1,473 $16,618 $16,895 $33,513 
Schedule of supplemental financial information related to collaboration and license agreements
Supplemental financial information related to the collaboration and license agreements for the three and nine months ended September 30, 2023 and 2022 are (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Revenue recognized that was included in the contract liability at the beginning of the period$11,028 $5,517 $16,923 $24,005 
Revenue recognized from performance obligations fully or partially satisfied in previous periods$43 $— $43 $518